Recombinant Influenza Virus M2 Mutation Microneedle Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current influenza vaccines face challenges in stability and effectiveness, particularly with live attenuated viruses that can revert to wild-type or non-wild-type sequences, and existing vaccines may not provide durable or cross-reactive immunity, and there is a need for improved methods to administer vaccines effectively.
Innovation Solution
A recombinant influenza virus with a mutation in the M gene that prevents expression of the M2 protein or results in a truncated protein, which is stable and non-pathogenic, is used in combination with a microneedle delivery device for intradermal administration to elicit a detectable immune response and provide protection against influenza.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated influenza virus vaccines are used, then immune response effectiveness and durability are improved, but virus stability deteriorates due to potential reversion to wild-type sequences
Solution Approach 1:
The patent divides the influenza virus genome into separate segments, with each segment expressing a specific antigen. This segmentation allows the virus to be attenuated (reduced pathogenicity) while maintaining immunogenicity, as the virus cannot revert to wild-type form without acquiring all necessary genetic changes across multiple segments simultaneously.
Solution Approach 2:
The patent extracts and removes the M2 gene from the influenza virus genome to create the attenuated vaccine strain. By taking out this essential gene, the virus loses its ability to cause disease while retaining the capacity to present other viral antigens to the immune system, thereby preventing reversion to pathogenic forms.
2Ease of operation
If conventional vaccine administration methods are used, then vaccine delivery is simple, but immunogenicity and effectiveness deteriorate
Solution Approach 1:
The patent employs microneedles with specific local properties (micro-scale dimensions, controlled geometry) to deliver vaccine directly to the immunologically active dermal layer. This local quality enhancement ensures high immunogenicity by targeting antigen-presenting cells in the skin, while the overall administration process remains simple and painless.
Solution Approach 2:
The patent changes the physical parameters of vaccine delivery by using microneedles instead of traditional hypodermic needles. This parameter change (from macro-scale needle insertion to micro-scale puncture) enhances immunogenicity through improved antigen delivery to immune cells, while maintaining ease of operation as the device requires minimal training to use.
Data Source
AI summary
Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.